MannKind Corp. announced the results of a two year study comparing the efficacy and safety of AFREZZA (insulin human [rDNA origin]) versus usual diabetes care.
The study followed patients for a total of up to two years. The patients were randomly assigned to a treatment regimen of either AFREZZA plus...






